The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Australian prescription medicine decision summaries
These decision summaries provide an overview of our evaluation process leading to the registration of a new prescription medicine.
For more information please visit the Australian prescription medicine decision summaries information page.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Search
226 result(s) found, displaying 126 to 150
-
Prescription medicine decision summaryTGA decision: Rholistiq (belumosudil mesilate) is approved to treat chronic graft-versus-host disease (GVHD)
-
Prescription medicine decision summaryTGA decision: Illuccix (Glu-urea-Lys(ahx)-hbed-CC) is a radioactive diagnostic agent used to assist in the treatment of prostate cancer.
-
Prescription medicine decision summaryTGA decision: Truseltiq (infigratinib) is approved to treat cholangiocarcinoma.
-
Prescription medicine decision summaryTGA decision: Bevacip/Bevaciptin (bevacizumab) is approved to treat various types of cancers.
-
Prescription medicine decision summaryTGA decision: VeraSeal (human fibrinogen/ human thrombin) is approved to treat hemostasis.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Prescription medicine decision summaryAustralian prescription medicine decision summary